Literature DB >> 1383293

Therapeutic alternatives in cutaneous T-cell lymphoma.

K B Holloway1, F P Flowers, F A Ramos-Caro.   

Abstract

Mycosis fungoides and Sézary syndrome, collectively referred to as cutaneous T-cell lymphoma, are non-Hodgkin's lymphomas that initially appear in the skin. Early-stage disease, limited to the skin, is best treated with sequential topical therapies such as topical nitrogen mustard, psoralen phototherapy (PUVA), or total-skin electron beam therapy. Photopheresis is the first line of therapy for the patient with erythroderma. Systemic therapy is generally reserved for patients with refractory disease and patients who initially present with extracutaneous involvement. Although there are several treatment options for cutaneous T-cell lymphoma, there have been few randomized comparative trials.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383293     DOI: 10.1016/0190-9622(92)70202-q

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Epitheliotropic lymphoma in a dog.

Authors:  H Bouchard
Journal:  Can Vet J       Date:  2000-08       Impact factor: 1.008

2.  Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma.

Authors:  M Di Renzo; P Rubegni; G De Aloe; L Paulesu; A L Pasqui; L Andreassi; A Auteri; M Fimiani
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

3.  Cutaneous T cell lymphomas.

Authors:  N Smith; M Spittle
Journal:  BMJ       Date:  1994-05-14

Review 4.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.

Authors:  B Prinz; W Behrens; E Hölzle; G Plewig
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.